ofloxacin has been researched along with Bronchitis in 72 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Bronchitis: Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This post hoc analysis of data from a previous randomized, blinded, multicenter, parallel, noninferiority study assessed the bacterial etiology, symptom resolution, and tolerability of severe acute bacterial exacerbation of chronic bronchitis (ABECB) patients treated with either levofloxacin 750 mg QD for 5 days or amoxicillin/clavulanate 875 mg/125 mg BID for 10 days." | 9.12 | Levofloxacin 750 mg QD for five days versus amoxicillin/clavulanate 875 mg/125 mg BID for ten days for treatment of acute bacterial exacerbation of chronic bronchitis: a post hoc analysis of data from severely ill patients. ( Ambrusz, ME; Fisher, AC; Grossman, RF; Kahn, JB; Khashab, MM, 2006) |
| "To demonstrate that 5 days of treatment with a new fluoroquinolone, gemifloxacin, is at least as effective as 7 days of treatment with levofloxacin in adult patients with acute exacerbation of chronic bronchitis (AECB)." | 9.11 | A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis. ( Fogarty, C; Fulambarker, A; Sethi, S, 2004) |
| "We previously reported that a 6-month low-dose course of ofloxacin combined with long-term low-dose erythromycin therapy (EM therapy) was superior to EM therapy alone for sinobronchial syndrome (SBS), especially during the initial 2 months of treatment." | 9.10 | Addition of a 2-month low-dose course of levofloxacin to long-term erythromycin therapy in sinobronchial syndrome. ( Fujimura, M; Mizuguchi, M; Mizuhashi, K; Nakatsumi, Y; Sasaki, S; Yasui, M, 2002) |
| "A randomized, double-blind, double-dummy, three-arm parallel design, multicentre study was conducted among adult patients with acute exacerbation of chronic bronchitis (AECB) in order to compare the efficacy and safety of two different doses of levofloxacin with cefuroxime axetil." | 9.09 | Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double-blind study. ( Dolmann, A; Fiss, E; Maesen, FP; Shah, PM; Vetter, N; Wesch, R, 1999) |
| "The objective of this randomized, double-blind study was to compare the clinical efficacy of levofloxacin at two different dosages with that of cefuroxime axetil in patients with acute purulent exacerbations of chronic bronchitis and, in particular, to assess the impact of the susceptibility to levofloxacin on the clinical findings." | 9.09 | Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in-vitro activity. ( Davies, BI; Maesen, FP, 1999) |
| "Comparison of efficacy and safety of sparfloxacin vs ofloxacin for treatment of acute bacterial exacerbations of chronic bronchitis (ABECB)." | 9.08 | Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: a multicenter, double-blind, randomized, comparative study. Sparfloxacin Multicenter ABECB Study Group. ( Bensch, G; Chodosh, S; DeAbate, CA; Harper, L; Henry, D; Jubran, A; Talbot, GH; Tipping, D, 1998) |
| "It has been established that long-term low-dose erythromycin therapy (EM therapy) is very effective for sinobronchial syndrome, a common condition in Japan characterized by chronic upper and lower airway inflammation." | 9.08 | Additive effect of continuous low-dose ofloxacin on erythromycin therapy for sinobronchial syndrome. ( Fujimura, M; Ishiura, Y; Matsuda, T; Nakatsumi, Y; Nomura, M; Saito, M; Shibata, K, 1995) |
| "128 Patients (45 female, 83 male) with acute exacerbations of chronic bronchitis were treated with either cefuroxime axetil 2 x 500 mg/d (n = 65) or ofloxacin 2 x 200 mg/d for 7-8 days in a randomized controlled multicenter trial." | 9.07 | [Treatment of acute exacerbations of chronic bronchitis. Multicenter, randomized comparative study of cefuroxime axetil versus ofloxacin]. ( Kleckow, M, 1991) |
| "In a double-blind study of 137 patients with exacerbation of chronic bronchitis and chronic obstructive lung disease, the efficacy and safety of ofloxacin was compared with that of trimethoprim-sulfamethoxazole (TMP/SMX)." | 9.07 | Double-blind comparative study of ofloxacin (Hoe 280) and trimethoprim-sulfamethoxazole in the treatment of patients with acute exacerbations of chronic bronchitis and chronic obstructive lung disease. ( Boye, NP; Gaustad, P, 1991) |
| "192 patients, most of them ambulatory, with acute exacerbation of chronic bronchitis were treated with 10- to 14-day courses of oral ofloxacin receiving 400 mg once daily or doxycycline first 200 mg and then 100 mg once daily in this randomized observer-blinded multicentre study." | 9.06 | Oral ofloxacin once daily and doxycycline in the treatment of acute exacerbations of chronic bronchitis. ( Ammälä, K; Aro, A; Backman, R; Keistinen, T; Lehtipuu, AL; Punakivi, L; Saarelainen, P; Veneskoski, T; Vilkka, V, 1990) |
| "In an open clinical trial, out-patients with respiratory tract infections were given 200 mg ofloxacin b." | 9.06 | [Respiratory tract infections--clinical results with ofloxacin]. ( Knothe, H; Shah, PM, 1986) |
| "The efficacy and tolerance of ofloxacin and doxycycline were compared in patients with lower respiratory tract infections." | 9.06 | An open randomised comparison of ofloxacin and doxycycline in lower respiratory tract infections. ( Harazim, H; Mittermayer, HP; Wimmer, J, 1987) |
| "The efficacy and safety of ofloxacin 400 mg once daily and amoxycillin/clavulanic acid 500/125 mg three times daily were compared in a double-blind manner in patients with an acute exacerbation of chronic bronchitis." | 9.06 | A double-blind comparison of low-dose ofloxacin and amoxycillin/clavulanic acid in acute exacerbations of chronic bronchitis. ( Beumer, HM; Hoepelman, IM; Möllers, MJ; Overbeek, BP; Rademaker, CM; Rozenberg-Arska, M; Sips, AP; Verhoef, J, 1990) |
| "Limited data suggest that tetracycline or erythromycin is the antibiotic of choice for treating Chlamydia pneumoniae infection, but they are not always effective or well tolerated." | 9.06 | Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections. ( Grayston, JT; Kuo, CC; Lipsky, BA; Tack, KJ; Wang, SP, 1990) |
| "In a double-blind study in 84 patients with chronic bronchitis and purulent exacerbations, ofloxacin 200 mg b." | 9.06 | A comparative study of ofloxacin and pivmecillinam in acute exacerbations of chronic bronchitis. ( Egede, F; Kristensen, I, 1990) |
| "Studies of acute exacerbations of chronic bronchitis (EXCB) included in the approval documents of levofloxacin (LVF) were reviewed in light of the good conditions of use defined by the French marketing approval and the AFSSAPS recommendations." | 7.72 | [Efficacy of levofloxacin in the treatment of acute exacerbation of chronic bronchitis in patients with risk factors]. ( Brumpt, I; Veyssier, P; Zuck, P, 2004) |
| "Levofloxacin is a fluoroquinolone antimicrobial agent for which pharmacodynamic relationships between the maximum serum antibiotic concentration (Cmax)/minimum inhibitory concentration (MIC) ratio and/or the area under the serum concentration-time curve during a 24-h dosing period (AUC(0-24))/MIC ratio and clinical and/or microbiological outcomes have been developed." | 6.71 | Pharmacodynamics of levofloxacin in patients with acute exacerbation of chronic bronchitis. ( Blasi, F; Cazzola, M; Donnarumma, G; Marchetti, F; Matera, MG; Sanduzzi, A; Tufano, MA, 2005) |
| "The patient was diagnosed with acute tubulointerstitial nephritis caused by cefdinir." | 5.31 | Successful steroid therapy for cefdinir-induced acute tubulointerstitial nephritis with progressive renal failure. ( Fujiwara, T; Hiramori, K; Kawamura, M; Kimura, Y; Maesawa, C; Owada, M, 2001) |
| "This post hoc analysis of data from a previous randomized, blinded, multicenter, parallel, noninferiority study assessed the bacterial etiology, symptom resolution, and tolerability of severe acute bacterial exacerbation of chronic bronchitis (ABECB) patients treated with either levofloxacin 750 mg QD for 5 days or amoxicillin/clavulanate 875 mg/125 mg BID for 10 days." | 5.12 | Levofloxacin 750 mg QD for five days versus amoxicillin/clavulanate 875 mg/125 mg BID for ten days for treatment of acute bacterial exacerbation of chronic bronchitis: a post hoc analysis of data from severely ill patients. ( Ambrusz, ME; Fisher, AC; Grossman, RF; Kahn, JB; Khashab, MM, 2006) |
| "To demonstrate that 5 days of treatment with a new fluoroquinolone, gemifloxacin, is at least as effective as 7 days of treatment with levofloxacin in adult patients with acute exacerbation of chronic bronchitis (AECB)." | 5.11 | A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis. ( Fogarty, C; Fulambarker, A; Sethi, S, 2004) |
| "We previously reported that a 6-month low-dose course of ofloxacin combined with long-term low-dose erythromycin therapy (EM therapy) was superior to EM therapy alone for sinobronchial syndrome (SBS), especially during the initial 2 months of treatment." | 5.10 | Addition of a 2-month low-dose course of levofloxacin to long-term erythromycin therapy in sinobronchial syndrome. ( Fujimura, M; Mizuguchi, M; Mizuhashi, K; Nakatsumi, Y; Sasaki, S; Yasui, M, 2002) |
| "The objective of this randomized, double-blind study was to compare the clinical efficacy of levofloxacin at two different dosages with that of cefuroxime axetil in patients with acute purulent exacerbations of chronic bronchitis and, in particular, to assess the impact of the susceptibility to levofloxacin on the clinical findings." | 5.09 | Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in-vitro activity. ( Davies, BI; Maesen, FP, 1999) |
| "A randomized, double-blind, double-dummy, three-arm parallel design, multicentre study was conducted among adult patients with acute exacerbation of chronic bronchitis (AECB) in order to compare the efficacy and safety of two different doses of levofloxacin with cefuroxime axetil." | 5.09 | Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double-blind study. ( Dolmann, A; Fiss, E; Maesen, FP; Shah, PM; Vetter, N; Wesch, R, 1999) |
| "Ofloxacin was used in the treatment of 15 patients (12 with pneumonia and 3 with aggravated chronic bronchitis)." | 5.08 | [Stepdown ofloxacin therapy in bronchopulmonary diseases]. ( Lenkova, NI; Makarova, OV; Nonikov, VE; Ritchik, LA, 1996) |
| "Comparison of efficacy and safety of sparfloxacin vs ofloxacin for treatment of acute bacterial exacerbations of chronic bronchitis (ABECB)." | 5.08 | Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: a multicenter, double-blind, randomized, comparative study. Sparfloxacin Multicenter ABECB Study Group. ( Bensch, G; Chodosh, S; DeAbate, CA; Harper, L; Henry, D; Jubran, A; Talbot, GH; Tipping, D, 1998) |
| "It has been established that long-term low-dose erythromycin therapy (EM therapy) is very effective for sinobronchial syndrome, a common condition in Japan characterized by chronic upper and lower airway inflammation." | 5.08 | Additive effect of continuous low-dose ofloxacin on erythromycin therapy for sinobronchial syndrome. ( Fujimura, M; Ishiura, Y; Matsuda, T; Nakatsumi, Y; Nomura, M; Saito, M; Shibata, K, 1995) |
| "Ofloxacin was used in the treatment of 24 patients with chronic bronchitis or pneumonia at the background of chronic bronchopulmonary and cardiovascular diseases." | 5.08 | [Clinical and pharmacokinetic evaluation of ofloxacin under various regimens of administration in patients with bronchopulmonary infections]. ( Belousov, OB; Efremenkova, OV; Gutkin, AB; Sokolov, AV; Tishchenkova, IF, 1996) |
| "128 Patients (45 female, 83 male) with acute exacerbations of chronic bronchitis were treated with either cefuroxime axetil 2 x 500 mg/d (n = 65) or ofloxacin 2 x 200 mg/d for 7-8 days in a randomized controlled multicenter trial." | 5.07 | [Treatment of acute exacerbations of chronic bronchitis. Multicenter, randomized comparative study of cefuroxime axetil versus ofloxacin]. ( Kleckow, M, 1991) |
| "Two different oral ofloxacin regimens, daily single-dose treatment with 200 mg (Regimen I) and every two week multidose treatment with 3 x 200 mg/day (Regimen II), were compared to evaluate the efficacy of quinolone regimens in controlling acute exacerbations of chronic respiratory tract infections." | 5.07 | Once daily versus every two week multidose ofloxacin in patients with acute exacerbations of chronic respiratory disease. ( Watanabe, A, 1991) |
| "In a double-blind study of 137 patients with exacerbation of chronic bronchitis and chronic obstructive lung disease, the efficacy and safety of ofloxacin was compared with that of trimethoprim-sulfamethoxazole (TMP/SMX)." | 5.07 | Double-blind comparative study of ofloxacin (Hoe 280) and trimethoprim-sulfamethoxazole in the treatment of patients with acute exacerbations of chronic bronchitis and chronic obstructive lung disease. ( Boye, NP; Gaustad, P, 1991) |
| "We made an open, noncomparative evaluation of ofloxacin, 400 mg orally bid for 10 days, in 98 subjects with community-acquired pneumonia or pathogen-confirmed bronchitis." | 5.07 | Oral ofloxacin therapy for lower respiratory tract infection. ( Farber, MO; Gentry, LO; Lipsky, B; Rodriguez-Gomez, G; Tucker, B, 1992) |
| "To assess the safety and efficacy of a ten-day oral course of ofloxacin (400 mg 12 hourly) as compared with erythromycin (400 mg every 6 hours) for treatment of lower respiratory tract infections, fifty-two adult outpatients with pulmonary infiltrates (pneumonia) or with a cough and purulent sputum (bronchitis) were evaluated." | 5.07 | Treatment of lower respiratory infections in outpatients with ofloxacin compared with erythromycin. ( Hooton, TM; Lipsky, BA; Pecoraro, RE; Peugeot, RL, 1991) |
| "In a double-blind study in 84 patients with chronic bronchitis and purulent exacerbations, ofloxacin 200 mg b." | 5.06 | A comparative study of ofloxacin and pivmecillinam in acute exacerbations of chronic bronchitis. ( Egede, F; Kristensen, I, 1990) |
| "Ofloxacin is highly active against common respiratory pathogens including Haemophilus influenzae and Branhamella catarrhalis and has clinically applicable activity against Streptococcus pneumoniae, Staphylococcus aureus and Pseudomonas aeruginosa." | 5.06 | Overview of experience with ofloxacin in respiratory tract infection. ( Ball, P, 1990) |
| "Limited data suggest that tetracycline or erythromycin is the antibiotic of choice for treating Chlamydia pneumoniae infection, but they are not always effective or well tolerated." | 5.06 | Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections. ( Grayston, JT; Kuo, CC; Lipsky, BA; Tack, KJ; Wang, SP, 1990) |
| "The efficacy and tolerance of ofloxacin and doxycycline were compared in patients with lower respiratory tract infections." | 5.06 | An open randomised comparison of ofloxacin and doxycycline in lower respiratory tract infections. ( Harazim, H; Mittermayer, HP; Wimmer, J, 1987) |
| "In an open clinical trial, out-patients with respiratory tract infections were given 200 mg ofloxacin b." | 5.06 | [Respiratory tract infections--clinical results with ofloxacin]. ( Knothe, H; Shah, PM, 1986) |
| "The efficacy and safety of ofloxacin 400 mg once daily and amoxycillin/clavulanic acid 500/125 mg three times daily were compared in a double-blind manner in patients with an acute exacerbation of chronic bronchitis." | 5.06 | A double-blind comparison of low-dose ofloxacin and amoxycillin/clavulanic acid in acute exacerbations of chronic bronchitis. ( Beumer, HM; Hoepelman, IM; Möllers, MJ; Overbeek, BP; Rademaker, CM; Rozenberg-Arska, M; Sips, AP; Verhoef, J, 1990) |
| "192 patients, most of them ambulatory, with acute exacerbation of chronic bronchitis were treated with 10- to 14-day courses of oral ofloxacin receiving 400 mg once daily or doxycycline first 200 mg and then 100 mg once daily in this randomized observer-blinded multicentre study." | 5.06 | Oral ofloxacin once daily and doxycycline in the treatment of acute exacerbations of chronic bronchitis. ( Ammälä, K; Aro, A; Backman, R; Keistinen, T; Lehtipuu, AL; Punakivi, L; Saarelainen, P; Veneskoski, T; Vilkka, V, 1990) |
| "Levofloxacin and sparfloxacin are active against pathogens frequently involved in community-acquired upper and lower respiratory tract infections, including Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Mycoplasma pneumoniae, Legionella pneumophila, and Chlamydia pneumoniae." | 4.80 | Levofloxacin and sparfloxacin: new quinolone antibiotics. ( Chuck, SK; Jung, R; Martin, SJ; Messick, CR; Meyer, JM; Pendland, SL, 1998) |
| "A 72-year-old female dialysis patient with insulin-dependent diabetes mellitus who was under long-term medication with oral prednisolone due to chronic obstructive pulmonary disease was given levofloxacin for one week to treat an acute bronchitis (one 500 mg dose on the first day, 125 mg/day orally from second day onwards)." | 3.74 | [Fluoroquinolone-induced Achilles tendon rupture]. ( Maurin, N, 2008) |
| "Studies of acute exacerbations of chronic bronchitis (EXCB) included in the approval documents of levofloxacin (LVF) were reviewed in light of the good conditions of use defined by the French marketing approval and the AFSSAPS recommendations." | 3.72 | [Efficacy of levofloxacin in the treatment of acute exacerbation of chronic bronchitis in patients with risk factors]. ( Brumpt, I; Veyssier, P; Zuck, P, 2004) |
| "To explore the effects of Zhikuofang, a TCM prescription, and Ofloxacin on the inflammation and cytostatics of the airway model of bronchiectasis." | 3.71 | [Effects of the zhikuofang on the inflammation and cytostatics of the airway model of bronchiectasis]. ( Bi, JJ; Cao, SH; Wan, YG; Zhou, M; Zhou, Y; Zhu, YH, 2002) |
| "This study was conducted to evaluate the activity of levofloxacin in comparison with a range of antibacterial agents against recent isolates obtained consecutively from patients with community-acquired pneumonia (CAP) or acute exacerbation of chronic bronchitis (AECB) during the period 1995 to 1996." | 3.70 | Comparative in-vitro activity of levofloxacin against isolates of bacteria from adult patients with community-acquired lower respiratory tract infections. ( Ariza, H; Ascoli, M; Casellas, JM; Dolmann, A; Gilardoni, M; Goldberg, M; Ivanovic, S; Montero, JM; Orduna, M; Tome, G, 1999) |
| "Sixty outpatients at the age of 65 to 75 years with exacerbated chronic bronchitis were treated with antibiotics: amoxycillin/clavulanic acid (20 patients), cefaclor (20 patients) and ciprofloxacin (20 patients)." | 3.69 | [Treatment of lower respiratory tract infections in the elderly]. ( Belousov, IuB; Efremenkova, OV; Komarova, VP; Sokolov, AV; Tishchenkova, IF, 1997) |
| " The patient, who was asthmatic and who was being treated with ofloxacin for bronchitis and pharyngitis, developed intense erythemas followed by subcorneal pustulation associated with fever and a neutrophil leukocytosis." | 3.68 | Toxic pustuloderma induced by ofloxacin. ( Inou, Y; Karashima, T; Kato, K; Sasai, Y; Tsuda, S, 1993) |
| "Ofloxacine (Tarivid-Hoechst) was used in 30 patients with infections of the respiratory system, including 12 with pneumonias, 18 with chronic bronchitis." | 3.68 | [Evaluation of the effectiveness of ofloxacin in the treatment of respiratory tract]. ( Chyrek-Borowska, S; Jakubicz, P; Siergiejko, Z, 1991) |
| "Simultaneous bronchial biopsy and serum samples were obtained from 14 patients after a single oral dose of 200 mg ofloxacin and from ten patients during the course of multiple dose oral treatment, (200 mg ofloxacin bd) for acute exacerbations of chronic bronchitis." | 3.68 | Bronchial penetration of ofloxacin after single and multiple oral dosage. ( Davey, PG; Precious, E; Winter, J, 1991) |
| "In order to determine the efficacy and safety of the new quinolone ofloxacin in the treatment of chronic lower respiratory disease, 674 patients (353 with chronic bronchitis, 212 with community-acquired pneumonia and 109 with hospital-acquired pneumonia) were treated with ofloxacin 200 mg twice a day." | 3.68 | Ofloxacin in lower respiratory tract infections. ( Petermann, W, 1991) |
| "Levofloxacin is a fluoroquinolone antimicrobial agent for which pharmacodynamic relationships between the maximum serum antibiotic concentration (Cmax)/minimum inhibitory concentration (MIC) ratio and/or the area under the serum concentration-time curve during a 24-h dosing period (AUC(0-24))/MIC ratio and clinical and/or microbiological outcomes have been developed." | 2.71 | Pharmacodynamics of levofloxacin in patients with acute exacerbation of chronic bronchitis. ( Blasi, F; Cazzola, M; Donnarumma, G; Marchetti, F; Matera, MG; Sanduzzi, A; Tufano, MA, 2005) |
| "Pneumonia was present in 31 percent of the patients and the remainder had purulent bronchitis." | 2.66 | Ofloxacin in community-acquired lower respiratory infections. A comparison with amoxicillin or erythromycin. ( Garcia, JG; Griffith, DE; Kohler, RB; Stocks, JM; Wallace, RJ, 1989) |
| "The patient was diagnosed with acute tubulointerstitial nephritis caused by cefdinir." | 1.31 | Successful steroid therapy for cefdinir-induced acute tubulointerstitial nephritis with progressive renal failure. ( Fujiwara, T; Hiramori, K; Kawamura, M; Kimura, Y; Maesawa, C; Owada, M, 2001) |
| "On the 7th day, he suffered generalized convulsions and was admitted." | 1.30 | [Levofloxacin-induced neurological adverse effects such as convulsion, involuntary movement (tremor, myoclonus and chorea like), visual hallucination in two elderly patients]. ( Fukayama, M; Inamatsu, T; Kita, Y; Masuda, Y; Yasuda, H; Yoshida, A, 1999) |
| "We describe 7 Achilles tendinitis occurring during fluoroquinolone treatment." | 1.28 | Seven Achilles tendinitis including 3 complicated by rupture during fluoroquinolone therapy. ( Audisio, F; De Bandt, M; Hayem, G; Jorgensen, C; Kahn, MF; Meyer, O; Palazzo, E; Ribard, P, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (16.67) | 18.7374 |
| 1990's | 35 (48.61) | 18.2507 |
| 2000's | 23 (31.94) | 29.6817 |
| 2010's | 2 (2.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kato, A | 1 |
| Ishigaki, S | 1 |
| Yasuda, H | 2 |
| Pubill-Fondevila, N | 1 |
| Bielsa, S | 1 |
| Porcel, JM | 1 |
| Zuck, P | 2 |
| Fujimura, M | 3 |
| Mizuguchi, M | 1 |
| Nakatsumi, Y | 3 |
| Mizuhashi, K | 1 |
| Sasaki, S | 1 |
| Yasui, M | 1 |
| Gonzales, R | 1 |
| Wan, YG | 1 |
| Cao, SH | 1 |
| Bi, JJ | 1 |
| Zhu, YH | 1 |
| Zhou, Y | 1 |
| Zhou, M | 1 |
| Shah, P | 1 |
| Blasi, F | 2 |
| Sethi, S | 1 |
| Fogarty, C | 1 |
| Fulambarker, A | 1 |
| Veyssier, P | 1 |
| Brumpt, I | 1 |
| Cazzola, M | 1 |
| Matera, MG | 1 |
| Donnarumma, G | 1 |
| Tufano, MA | 1 |
| Sanduzzi, A | 1 |
| Marchetti, F | 1 |
| Giamarellou, H | 1 |
| Kanellakopoulou, K | 1 |
| Brückner, O | 1 |
| Trautmann, M | 1 |
| Martinez, FJ | 1 |
| Grossman, RF | 1 |
| Ambrusz, ME | 1 |
| Fisher, AC | 1 |
| Khashab, MM | 1 |
| Kahn, JB | 1 |
| Vyas, H | 1 |
| Krishnaswamy, G | 1 |
| Maurin, N | 1 |
| Tazi, A | 1 |
| Gueudet, T | 1 |
| Varon, E | 1 |
| Gilly, L | 1 |
| Trieu-Cuot, P | 1 |
| Poyart, C | 1 |
| Kobayashi, H | 1 |
| Takamura, K | 1 |
| Kono, K | 1 |
| Onodera, S | 1 |
| Sasaki, N | 1 |
| Nagahama, F | 1 |
| Kawakami, Y | 1 |
| Honma, Y | 1 |
| Matsuzaki, M | 1 |
| Tanimura, K | 1 |
| Fujimori, I | 1 |
| Kobayashi, Y | 1 |
| Obana, M | 1 |
| Saito, A | 1 |
| Tomizawa, M | 1 |
| Nakayama, I | 1 |
| Hiraga, Y | 1 |
| Kikuchi, K | 1 |
| Yamamoto, A | 1 |
| Takebe, K | 1 |
| Savitskaia, KI | 1 |
| Tsar'kova, LN | 1 |
| Shanina, AG | 1 |
| Nasonov, VN | 1 |
| Solodilova, OE | 1 |
| Rusanova, EV | 1 |
| Tsuda, S | 1 |
| Kato, K | 1 |
| Karashima, T | 1 |
| Inou, Y | 1 |
| Sasai, Y | 1 |
| Ishiura, Y | 2 |
| Saito, M | 2 |
| Shibata, K | 2 |
| Nomura, M | 2 |
| Matsuda, T | 2 |
| Odagiri, S | 1 |
| Hollweg, M | 1 |
| Kapfhammer, HP | 1 |
| Belousov, OB | 1 |
| Gutkin, AB | 1 |
| Sokolov, AV | 3 |
| Tishchenkova, IF | 2 |
| Efremenkova, OV | 3 |
| Nonikov, VE | 1 |
| Lenkova, NI | 1 |
| Makarova, OV | 1 |
| Ritchik, LA | 1 |
| Komarova, VP | 1 |
| Belousov, IuB | 2 |
| Martin, SJ | 1 |
| Meyer, JM | 1 |
| Chuck, SK | 1 |
| Jung, R | 1 |
| Messick, CR | 1 |
| Pendland, SL | 1 |
| DeAbate, CA | 1 |
| Henry, D | 1 |
| Bensch, G | 1 |
| Jubran, A | 1 |
| Chodosh, S | 2 |
| Harper, L | 1 |
| Tipping, D | 1 |
| Talbot, GH | 1 |
| Shah, PM | 3 |
| Maesen, FP | 5 |
| Dolmann, A | 2 |
| Vetter, N | 1 |
| Fiss, E | 1 |
| Wesch, R | 1 |
| Yoshida, A | 1 |
| Masuda, Y | 1 |
| Fukayama, M | 1 |
| Kita, Y | 1 |
| Inamatsu, T | 1 |
| Casellas, JM | 1 |
| Gilardoni, M | 1 |
| Tome, G | 1 |
| Goldberg, M | 1 |
| Ivanovic, S | 1 |
| Orduna, M | 1 |
| Ascoli, M | 1 |
| Ariza, H | 1 |
| Montero, JM | 1 |
| Davies, BI | 4 |
| Tishenkova, IF | 1 |
| Guseĭnov, KhIu | 1 |
| Douadi, Y | 1 |
| Lescure, X | 1 |
| Schmit, JL | 1 |
| Scheen, AJ | 1 |
| Li-McLeod, J | 1 |
| Perfetto, EM | 1 |
| Kimura, Y | 1 |
| Kawamura, M | 1 |
| Owada, M | 1 |
| Fujiwara, T | 1 |
| Maesawa, C | 1 |
| Hiramori, K | 1 |
| Budanov, SV | 1 |
| Vasil'ev, AN | 1 |
| Smirnova, LB | 1 |
| Ribard, P | 1 |
| Audisio, F | 1 |
| Kahn, MF | 1 |
| De Bandt, M | 1 |
| Jorgensen, C | 1 |
| Hayem, G | 1 |
| Meyer, O | 1 |
| Palazzo, E | 1 |
| Gentry, LO | 1 |
| Lipsky, B | 1 |
| Farber, MO | 1 |
| Tucker, B | 1 |
| Rodriguez-Gomez, G | 1 |
| Peugeot, RL | 1 |
| Lipsky, BA | 2 |
| Hooton, TM | 1 |
| Pecoraro, RE | 1 |
| Petermann, W | 1 |
| Watanabe, A | 1 |
| Boye, NP | 1 |
| Gaustad, P | 1 |
| Chyrek-Borowska, S | 1 |
| Siergiejko, Z | 1 |
| Jakubicz, P | 1 |
| Thys, JP | 1 |
| Jacobs, F | 1 |
| Byl, B | 1 |
| Kleckow, M | 1 |
| Davey, PG | 1 |
| Precious, E | 1 |
| Winter, J | 1 |
| Yamaoka, M | 1 |
| Fukuchi, Y | 1 |
| Yokouchi, M | 1 |
| Teramoto, N | 1 |
| Nagase, T | 1 |
| Ishida, K | 1 |
| Ohtomo, E | 1 |
| Orimo, H | 1 |
| De Simone, C | 1 |
| Di Fabio, S | 1 |
| Moretti, S | 1 |
| Tzantzoglou, S | 1 |
| Trinchieri, V | 1 |
| Gargiulo, M | 1 |
| Punakivi, L | 1 |
| Keistinen, T | 1 |
| Backman, R | 1 |
| Lehtipuu, AL | 1 |
| Saarelainen, P | 1 |
| Vilkka, V | 1 |
| Veneskoski, T | 1 |
| Ammälä, K | 1 |
| Aro, A | 1 |
| Egede, F | 2 |
| Kristensen, I | 2 |
| Ball, P | 1 |
| Tack, KJ | 1 |
| Kuo, CC | 1 |
| Wang, SP | 1 |
| Grayston, JT | 1 |
| Rademaker, CM | 1 |
| Sips, AP | 1 |
| Beumer, HM | 1 |
| Hoepelman, IM | 1 |
| Overbeek, BP | 1 |
| Möllers, MJ | 1 |
| Rozenberg-Arska, M | 1 |
| Verhoef, J | 1 |
| Stocks, JM | 1 |
| Wallace, RJ | 1 |
| Griffith, DE | 1 |
| Garcia, JG | 1 |
| Kohler, RB | 1 |
| Teengs, JP | 2 |
| Baur, C | 3 |
| Geraedts, WH | 1 |
| Sugimoto, Y | 1 |
| Matsumoto, Y | 1 |
| Hitsuda, Y | 1 |
| Yamamoto, Y | 1 |
| Ishitobi, K | 1 |
| Sasaki, T | 1 |
| Harazim, H | 1 |
| Wimmer, J | 1 |
| Mittermayer, HP | 1 |
| Knothe, H | 1 |
7 reviews available for ofloxacin and Bronchitis
| Article | Year |
|---|---|
Role of levofloxacin in the treatment of lower respiratory tract infections (LRTIs).
Topics: Administration, Oral; Anti-Infective Agents; Bronchitis; Chronic Disease; Community-Acquired Infecti | 2004 |
Acute exacerbation of chronic bronchitis: expanding short-course therapy.
Topics: Acute Disease; Aged; Anti-Bacterial Agents; Azithromycin; Bronchitis; Clinical Trials as Topic; Conf | 2005 |
Levofloxacin and sparfloxacin: new quinolone antibiotics.
Topics: Absorption; Anti-Infective Agents; Bronchitis; Drug Interactions; Drug Resistance, Microbial; Fluoro | 1998 |
The use of levofloxacin in the treatment of respiratory tract infection.
Topics: Anti-Infective Agents; Bronchitis; Chronic Disease; Community-Acquired Infections; Haemophilus Infec | 2000 |
[The first 'respiration' fluoroquinolone--levofloxacin (Tavanic) in therapy of bacterial infections. Pharmacodynamics principles in optimization of administration regimens].
Topics: Acute Disease; Animals; Anti-Infective Agents; Bronchitis; Chronic Disease; Community-Acquired Infec | 2001 |
Use of quinolones for the treatment of acute exacerbations of chronic bronchitis.
Topics: Acute Disease; Anti-Infective Agents; Bronchitis; Chronic Disease; Ciprofloxacin; Fluoroquinolones; | 1991 |
Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia.
Topics: Anti-Infective Agents; Bronchitis; Ciprofloxacin; Drug Therapy, Combination; Enoxacin; Humans; Oflox | 1991 |
32 trials available for ofloxacin and Bronchitis
| Article | Year |
|---|---|
Addition of a 2-month low-dose course of levofloxacin to long-term erythromycin therapy in sinobronchial syndrome.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Bronchiolitis; Bronchitis; Drug Therapy, Combina | 2002 |
A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis.
Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Bronchitis; Chronic Disease; Double-Blind | 2004 |
Pharmacodynamics of levofloxacin in patients with acute exacerbation of chronic bronchitis.
Topics: Acute Disease; Aged; Anti-Bacterial Agents; Area Under Curve; Bronchitis; Disease Progression; Femal | 2005 |
Levofloxacin 750 mg QD for five days versus amoxicillin/clavulanate 875 mg/125 mg BID for ten days for treatment of acute bacterial exacerbation of chronic bronchitis: a post hoc analysis of data from severely ill patients.
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacterial Infections; Br | 2006 |
[Comparison of DL-8280 and amoxicillin in the treatment of respiratory tract infections].
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bronchiectasis; Bronchitis; Clinical Trials as Topi | 1984 |
[Comparative clinical study of ofloxacin and cefaclor in bacterial bronchitis].
Topics: Adult; Aged; Anti-Infective Agents; Bacterial Infections; Bronchitis; Cefaclor; Cephalexin; Clinical | 1984 |
[Use of ofloxacin in the treatment of infections of the lower respiratory tract].
Topics: Adolescent; Adult; Asthma; Bronchitis; Chronic Disease; Female; Gram-Negative Bacterial Infections; | 1994 |
Additive effect of continuous low dose ofloxacin on erythromycin therapy for sinobronchial syndrome.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Bronchitis; Drug Thera | 1995 |
Additive effect of continuous low-dose ofloxacin on erythromycin therapy for sinobronchial syndrome.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bronchitis; Carbocysteine; Drug Administratio | 1995 |
[Clinical and pharmacokinetic evaluation of ofloxacin under various regimens of administration in patients with bronchopulmonary infections].
Topics: Administration, Oral; Anti-Infective Agents; Bronchitis; Cardiovascular Diseases; Drug Administratio | 1996 |
[Stepdown ofloxacin therapy in bronchopulmonary diseases].
Topics: Administration, Oral; Anti-Infective Agents; Bronchitis; Chronic Disease; Drug Administration Schedu | 1996 |
Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: a multicenter, double-blind, randomized, comparative study. Sparfloxacin Multicenter ABECB Study Group.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bronchitis; Chlamy | 1998 |
Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double-blind study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bronchitis; Cefuroxime; Cephalosporins; Chron | 1999 |
Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in-vitro activity.
Topics: Aged; Anti-Infective Agents; Bronchitis; Cefuroxime; Cephalosporins; Chronic Disease; Double-Blind M | 1999 |
[The importance of fluoroquinolones in treating pneumonia in the elderly].
Topics: Aged; Anti-Infective Agents; Bronchitis; Chronic Disease; Dose-Response Relationship, Drug; Fluoroqu | 1999 |
Oral ofloxacin therapy for lower respiratory tract infection.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Bronchitis; Drug Administration S | 1992 |
Treatment of lower respiratory infections in outpatients with ofloxacin compared with erythromycin.
Topics: Adult; Aged; Bronchitis; Chlamydia Infections; Erythromycin; Female; Humans; Legionnaires' Disease; | 1991 |
Once daily versus every two week multidose ofloxacin in patients with acute exacerbations of chronic respiratory disease.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Bacterial Infections; Bronchiectasis; Bronchitis; Chr | 1991 |
Double-blind comparative study of ofloxacin (Hoe 280) and trimethoprim-sulfamethoxazole in the treatment of patients with acute exacerbations of chronic bronchitis and chronic obstructive lung disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bronchitis; Chronic Disease; Double-Blind Method; Female | 1991 |
Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia.
Topics: Anti-Infective Agents; Bronchitis; Ciprofloxacin; Drug Therapy, Combination; Enoxacin; Humans; Oflox | 1991 |
[Treatment of acute exacerbations of chronic bronchitis. Multicenter, randomized comparative study of cefuroxime axetil versus ofloxacin].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Bronchitis; Cefuroxime; Chronic Di | 1991 |
Open randomized controlled parallel study of ofloxacin versus trimethoprim-sulfamethoxazole treatment of lower respiratory tract and urinary infections.
Topics: Acute Disease; Aged; Bronchitis; Bronchopneumonia; Chronic Disease; Cystitis; Escherichia coli; Fema | 1991 |
Oral ofloxacin once daily and doxycycline in the treatment of acute exacerbations of chronic bronchitis.
Topics: Administration, Oral; Bronchitis; Chronic Disease; Doxycycline; Drug Administration Schedule; Female | 1990 |
A comparative study of ofloxacin and pivmecillinam in acute exacerbations of chronic bronchitis.
Topics: Adult; Aged; Aged, 80 and over; Amdinocillin Pivoxil; Bronchitis; Chronic Disease; Double-Blind Meth | 1990 |
Overview of experience with ofloxacin in respiratory tract infection.
Topics: Bronchitis; Chronic Disease; Humans; Ofloxacin; Pneumonia; Remission Induction; Respiratory Tract In | 1990 |
Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections.
Topics: Aged; Bronchitis; Chlamydia; Chlamydia Infections; Clinical Trials as Topic; Drug Resistance, Microb | 1990 |
A double-blind comparison of low-dose ofloxacin and amoxycillin/clavulanic acid in acute exacerbations of chronic bronchitis.
Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Bronchitis; Chronic Disease; Clavulanic | 1990 |
Ofloxacin in community-acquired lower respiratory infections. A comparison with amoxicillin or erythromycin.
Topics: Adult; Amoxicillin; Bronchitis; Erythromycin; Female; Humans; Lung Diseases, Obstructive; Male; Midd | 1989 |
A clinical comparative study of ofloxacin and pivampicillin in acute exacerbations of chronic bronchitis.
Topics: Acute Disease; Ampicillin; Bronchitis; Double-Blind Method; Female; Humans; Male; Ofloxacin; Pivampi | 1988 |
The use of quinolones in respiratory tract infections.
Topics: Anti-Infective Agents; Bronchitis; Chronic Disease; Clinical Trials as Topic; Humans; Microbial Sens | 1987 |
An open randomised comparison of ofloxacin and doxycycline in lower respiratory tract infections.
Topics: Anti-Infective Agents; Bronchitis; Chronic Disease; Doxycycline; Humans; Microbial Sensitivity Tests | 1987 |
[Respiratory tract infections--clinical results with ofloxacin].
Topics: Adult; Anti-Bacterial Agents; Bacterial Infections; Bronchitis; Chronic Disease; Clinical Trials as | 1986 |
34 other studies available for ofloxacin and Bronchitis
| Article | Year |
|---|---|
Levofloxacin-associated Achilles tendinitis in a patient with chronic kidney disease stage 5.
Topics: Achilles Tendon; Bronchitis; Female; Humans; Kidney Failure, Chronic; Levofloxacin; Magnetic Resonan | 2011 |
[Levofloxacin hepatotoxicity].
Topics: Adult; Alanine Transaminase; Anti-Bacterial Agents; Aspartate Aminotransferases; Bronchiectasis; Bro | 2013 |
[Update on the use of levofloxacin in the management of acute exacerbations of chronic bronchitis with risk factors].
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Infective Agents; Bronchitis; Chron | 2002 |
[Fluoroquinolone superior to macrolide. Longer infection free period after acute bronchitis].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Bronchitis; Clarithromycin; Doub | 2003 |
A 65-year-old woman with acute cough illness and an important engagement.
Topics: Acute Disease; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Antitussive Agents; Antiviral Age | 2003 |
[Effects of the zhikuofang on the inflammation and cytostatics of the airway model of bronchiectasis].
Topics: Animals; Anti-Infective Agents; Bronchiectasis; Bronchitis; Drug Combinations; Drugs, Chinese Herbal | 2002 |
[Do tendon lesions occur during quinolone administration?].
Topics: Achilles Tendon; Adult; Age Factors; Anti-Infective Agents; Bronchitis; Ciprofloxacin; Enzyme Inhibi | 2003 |
[Efficacy of levofloxacin in the treatment of acute exacerbation of chronic bronchitis in patients with risk factors].
Topics: Acute Disease; Anti-Bacterial Agents; Bronchitis; Chronic Disease; Clinical Trials as Topic; Humans; | 2004 |
A review of the therapeutic uses of ofloxacin.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Bronchitis; Chronic | 1989 |
Efficacy and safety in the oral treatment of purulent chest disease and pneumonia with cefixime, ofloxacin, and ciprofloxacin.
Topics: Administration, Oral; Anti-Bacterial Agents; Bronchitis; Cefixime; Ciprofloxacin; Clinical Trials as | 1989 |
Images in clinical medicine. Quinolone-associated rupture of the Achilles' tendon.
Topics: Achilles Tendon; Aged, 80 and over; Anti-Bacterial Agents; Bronchitis; Female; Humans; Magnetic Reso | 2007 |
[Fluoroquinolone-induced Achilles tendon rupture].
Topics: Achilles Tendon; Aged; Anti-Bacterial Agents; Bronchitis; Diabetes Mellitus, Type 1; Female; Humans; | 2008 |
Fluoroquinolone-resistant group B streptococci in acute exacerbation of chronic bronchitis.
Topics: Acute Disease; Aged, 80 and over; Anti-Bacterial Agents; Bronchitis; Chronic Disease; DNA Gyrase; Dr | 2008 |
Toxic pustuloderma induced by ofloxacin.
Topics: Bronchitis; Drug Eruptions; Female; Humans; Middle Aged; Ofloxacin; Pharyngitis; Skin; Skin Diseases | 1993 |
Levofloxacin in patients with severe respiratory tract infection.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Asthma; Bronchitis; Chronic Disease; Clarithromy | 1995 |
[Paranoid psychosis after treatment with the antibiotic ofloxacin].
Topics: Adult; Anti-Infective Agents; Bronchitis; Dose-Response Relationship, Drug; Humans; Male; Ofloxacin; | 1996 |
Sparfloxacin and levofloxacin.
Topics: Administration, Oral; Anti-Infective Agents; Bronchitis; Chronic Disease; Clinical Trials as Topic; | 1997 |
[Treatment of lower respiratory tract infections in the elderly].
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; A | 1997 |
[Levofloxacin-induced neurological adverse effects such as convulsion, involuntary movement (tremor, myoclonus and chorea like), visual hallucination in two elderly patients].
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Bronchitis; Dyskinesia, Drug-Induced; Hallucinations | 1999 |
Comparative in-vitro activity of levofloxacin against isolates of bacteria from adult patients with community-acquired lower respiratory tract infections.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacteria; Bronchitis; Chronic Disease; Commun | 1999 |
[Use of antibiotics in chronic bronchitis].
Topics: Administration, Oral; Adult; Ampicillin; Anti-Infective Agents; Bronchitis; Chronic Disease; Female; | 2000 |
[A new antibiotic: levofloxacine].
Topics: Anti-Infective Agents; Bronchitis; Community-Acquired Infections; Humans; Ofloxacin; Pneumonia; Sinu | 2000 |
[Pharma-clinics. The drug of the month. Levofloxacin (Tavanic)].
Topics: Acute Disease; Anti-Infective Agents; Anti-Infective Agents, Urinary; Bacterial Infections; Bronchit | 2000 |
Workplace costs associated with acute exacerbation of chronic bronchitis: a comparison of moxifloxacin and levofloxacin.
Topics: Absenteeism; Adolescent; Adult; Anti-Infective Agents; Bronchitis; Chronic Disease; Cost of Illness; | 2001 |
Successful steroid therapy for cefdinir-induced acute tubulointerstitial nephritis with progressive renal failure.
Topics: Acute Disease; Acute Kidney Injury; Anti-Infective Agents; Anti-Inflammatory Agents; Biopsy; Bronchi | 2001 |
[Chronic bronchitis. What antibiotic in acute exacerbations. Good and fast effectiveness is needed].
Topics: Aged; Anti-Infective Agents; Bronchitis; Chronic Disease; Female; Humans; Male; Middle Aged; Ofloxac | 2002 |
Seven Achilles tendinitis including 3 complicated by rupture during fluoroquinolone therapy.
Topics: Achilles Tendon; Aged; Aged, 80 and over; Anti-Infective Agents; Bronchitis; Cystitis; Female; Human | 1992 |
Ofloxacin in lower respiratory tract infections.
Topics: Bacterial Infections; Bronchitis; Chronic Disease; Cross Infection; Drug Administration Schedule; Dr | 1991 |
[Evaluation of the effectiveness of ofloxacin in the treatment of respiratory tract].
Topics: Administration, Oral; Adult; Aged; Bronchitis; Chronic Disease; Drug Resistance, Microbial; Enteroco | 1991 |
Bronchial penetration of ofloxacin after single and multiple oral dosage.
Topics: Administration, Oral; Adult; Bronchi; Bronchitis; Chronic Disease; Drug Administration Schedule; Fem | 1991 |
Efficacy of oral administration of ofloxacin in lower respiratory tract infections in aged patients with chronic lung disease.
Topics: Administration, Oral; Aged; Aged, 80 and over; Bacterial Infections; Bronchitis; Chronic Disease; Fe | 1991 |
[New oral quinolone compounds in chronic bronchitis].
Topics: Administration, Oral; Anti-Bacterial Agents; Bacterial Infections; Bronchitis; Chronic Disease; Cipr | 1986 |
Quinolone antimicrobial agents in acute exacerbations of chronic bronchitis.
Topics: Anti-Infective Agents; Bacterial Infections; Bronchitis; Ciprofloxacin; Enoxacin; Female; Humans; Ma | 1986 |
[In vitro antibacterial activity and pharmacokinetics of ofloxacin in chronic respiratory tract infections].
Topics: Anti-Bacterial Agents; Bacteria; Bronchitis; Chronic Disease; Drug Resistance, Microbial; Humans; Of | 1987 |